Published in Vaccine on August 04, 2009
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.88
Advances in the development of cancer immunotherapies. Trends Immunol (2012) 0.96
The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Expert Rev Clin Pharmacol (2011) 0.88
CpG Oligonucleotides as Cancer Vaccine Adjuvants. Vaccines (Basel) (2015) 0.87
Transcutaneous antigen delivery system. BMB Rep (2013) 0.80
Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. Cancer Immunol Res (2015) 0.78
Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research. Biomed Res Int (2013) 0.78
Topical resiquimod: a promising adjuvant for vaccine development? Expert Rev Vaccines (2010) 0.77
Topical CpG adjuvantation of a protein-based vaccine induces protective immunity to Listeria monocytogenes. Clin Vaccine Immunol (2014) 0.77
Regional immune response to immunization with Escherichia coli O157:H7-derived intimin in cattle. Clin Vaccine Immunol (2013) 0.76
Toll-like receptors and cutaneous melanoma. Oncol Lett (2016) 0.75
Retrovirus-based Virus-Like Particle Immunogenicity and its Modulation by Toll-Like Receptor Activation. J Virol (2017) 0.75
Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol (2007) 4.36
Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest (2003) 2.37
Usefulness of Interferon-γ release assays in the diagnosis of erythema induratum. Arch Dermatol (2011) 1.40
In situ beta cell death promotes priming of diabetogenic CD8 T lymphocytes. J Immunol (2002) 1.30
Expansion of antigen-specific regulatory T cells with the topical vitamin d analog calcipotriol. J Immunol (2009) 1.26
New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther (2007) 1.24
Phagocytosis of apoptotic cells by macrophages from NOD mice is reduced. Diabetes (2002) 1.20
Optimization of epicutaneous immunization for the induction of CTL. Vaccine (2003) 1.19
Decidual NK cells alter in vitro first trimester extravillous cytotrophoblast migration: a role for IFN-gamma. J Immunol (2006) 1.17
Better influenza vaccines for older people: what will it take? J Infect Dis (2008) 1.17
Pathophysiology of cutaneous lupus erythematosus. Clin Rev Allergy Immunol (2007) 1.11
TLR9 blockade inhibits activation of diabetogenic CD8+ T cells and delays autoimmune diabetes. J Immunol (2010) 1.09
Molecular markers of early-stage mycosis fungoides. J Invest Dermatol (2012) 1.04
Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford) (2011) 1.00
Tolerance induction by transcutaneous immunization through ultraviolet-irradiated skin is transferable through CD4+CD25+ T regulatory cells and is dependent on host-derived IL-10. J Immunol (2006) 1.00
Active vitamin D (1,25-dihydroxyvitamin D3) increases host susceptibility to Citrobacter rodentium by suppressing mucosal Th17 responses. Am J Physiol Gastrointest Liver Physiol (2012) 0.95
Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach. J Am Acad Dermatol (2013) 0.94
Topical CpG enhances the response of murine malignant melanoma to dacarbazine. J Invest Dermatol (2008) 0.93
Thymocyte selection-associated high mobility group box gene (TOX) is aberrantly over-expressed in mycosis fungoides and correlates with poor prognosis. Oncotarget (2014) 0.92
Reversible retiform purpura: a sign of cocaine use. CMAJ (2011) 0.92
Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles. Int Immunol (2009) 0.90
Epicutaneous application of CpG oligodeoxynucleotides with peptide or protein antigen promotes the generation of CTL. J Invest Dermatol (2004) 0.89
Psychiatric disorders in patients with immune-mediated inflammatory diseases: prevalence, association with disease activity, and overall patient well-being. J Rheumatol Suppl (2011) 0.85
Treatment of atypical nevi with imiquimod 5% cream. Arch Dermatol (2007) 0.85
Islet allograft rejection is independent of toll-like receptor signaling in mice. Transplantation (2009) 0.85
Type 1 IFN-induced protein MxA and plasmacytoid dendritic cells in lesions of morphea. Exp Dermatol (2012) 0.83
Chronic granulomatous disease with unusual clinical manifestation, outcome, and pattern of inheritance in an Iranian family. J Clin Immunol (2006) 0.83
CD44 interacts directly with Lck in a zinc-dependent manner. Mol Immunol (2010) 0.83
IFN-gamma-mediated extravillous trophoblast outgrowth inhibition in first trimester explant culture: a role for insulin-like growth factors. Mol Hum Reprod (2008) 0.83
Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do. Eur J Immunol (2007) 0.82
Murine models of cutaneous involvement in lupus erythematosus. Autoimmun Rev (2009) 0.82
Hyaluronan binding identifies the most proliferative activated and memory T cells. Eur J Immunol (2011) 0.81
Subdomain X of the kinase domain of Lck binds CD45 and facilitates dephosphorylation. J Biol Chem (2003) 0.81
Tyrosine phosphorylation in immune cells: direct and indirect effects on toll-like receptor-induced proinflammatory cytokine production. Crit Rev Immunol (2009) 0.81
Progression of spontaneous autoimmune diabetes is associated with a switch in the killing mechanism used by autoreactive CTL. Int Immunol (2004) 0.80
The noncatalytic domains of Lck regulate its dephosphorylation by CD45. Biochim Biophys Acta (2003) 0.79
Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo. Br J Pharmacol (2013) 0.78
Inhibition of cathepsin S reduces allogeneic T cell priming but not graft-versus-host disease against minor histocompatibility antigens. Biol Blood Marrow Transplant (2011) 0.78
Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes. Vaccine (2004) 0.78
Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo. Br J Pharmacol (2013) 0.78
Skin immune responses to peptide and protein antigen are TLR4 independent. Cell Immunol (2003) 0.78
Decidual NK cell-derived conditioned medium (dNK-CM) mediates VEGF-C secretion in extravillous cytotrophoblasts. Am J Reprod Immunol (2011) 0.77
Topical CpG adjuvantation of a protein-based vaccine induces protective immunity to Listeria monocytogenes. Clin Vaccine Immunol (2014) 0.77
Tumor necrosis factor-a inhibition and palmoplantar pustulosis: Janus-faced therapy? J Rheumatol (2007) 0.77
Atrophie blanche: is it associated with venous disease or livedoid vasculopathy? Adv Skin Wound Care (2014) 0.77
Quality of life in patients with immune-mediated inflammatory diseases. J Rheumatol Suppl (2011) 0.77
Clinical and genetic registries in psoriatic disease. J Rheumatol (2008) 0.76
Combination Therapy With Tofacitinib and IL-12/23, IL-23, or IL-17A Inhibition for the Treatment of Refractory Psoriatic Arthritis: A Case Series. J Clin Rheumatol (2022) 0.75
Making necrotizing vasculitis simple. J Cutan Med Surg (2013) 0.75
Immunosuppression/Infections across Indications. Curr Probl Dermatol (2017) 0.75